Purchase this article with an account.
C. Simader, S. Michels, F. Prager, W. Geitzenauer, M. Georgopoulos, K. Polak, U. Schmidt-Erfurth; Intravitreal Bevacizumab (Avastin®) in Patients With Bilateral, Idiopathic, Acquired Parafoveolar Telangiectasis (2A). Invest. Ophthalmol. Vis. Sci. 2007;48(13):4146.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate intravitreal bevacizumab in patients with bilateral, idiopathic, acquired parafoveolar telangiectasis (2A)
In a retrospective study the effect and safety of intravitreal bevacizumab (Avastin®) in 10 eyes of 8 patients with bilateral parafoveolar telangiectasis (group 2A) stages 3 to 5 were evaluated. Retreatment was based on fluorescein angiography (FA) and clinical appearance. Patients were monitored using visual acuity (VA), fluorescein angiography (FA), biomicroscopy and optical coherence tomography (OCT).
No safety concerns were apparent in up to 13 months (mean 5.5 months) follow-up. All eyes showed a reduction or resolution of leakage in FA at 1 month follow-up associated with an improvement in visual acuity. Mean visual acuity improved from 20/63 at baseline to 20/40 at month 3. Central retinal thickness (CRT) as measured by OCT was moderately reduced within the first 3 months from 247µm to 192µm. At the last follow-up visit (mean 5.5 months) VA remained stable at 20/40. The mean number of treatments required was 1.9.
Intravitreal bevacizumab appears a promising treatment option for bilateral, idiopathic, acquired parafoveolar telangiectasis (2A) in short term follow-up.
This PDF is available to Subscribers Only